Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris
Status:
Recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of ixekizumab in lichen planus and lichen planopilaris
clinical response by Total Body Surface (TBS) determination, Investigator Global Assessment
(IGA) Score, Lichen Planopilaris Activity Index (LPPAI), and Frontal Fibrosing Alopecia
Severity Score (FFASS).